We identified that glucocorticoid-induced @entity170 management (bone mineral density testing or @entity170 treatment) among seniors improved among @entity1 (2 to 23 %) and @entity1 (10 to 48 %) between 1996 and 2007, and then remained relatively stable through to 2012. Differences were also noted by indication (from a low of 21 % for respiratory conditions to a high of 41 % for @entity627 ). PURPOSE: The aim of our study was to describe the proportion of chronic oral glucocorticoid (GC) users that receive @entity170 management (bone mineral density test or @entity170 treatment) by sex and over time. METHODS: We identified community-dwelling older adults initiating chronic oral GC therapy in Ontario using pharmacy data from 1996 to 2012. Chronic GC use was defined as greater than or equal to two oral GC prescriptions dispensed and >= 450 mg @entity229 equivalent over a 6-month period. @entity170 management within 6 months of starting chronic GC therapy was examined by sex, year, indication for therapy, and @entity170 management history. Results were summarized using descriptive statistics. RESULTS: We identified 72,099 @entity1 and 95,975 @entity1 starting chronic oral GC therapy (mean age   =   74.9 years, SD   =   6.5). Approximately two thirds of @entity1 (65 %) received >= 900 mg within the 6-month chronic use window. GC-induced @entity170 management increased from 2 to 23 % ( @entity1 ) and 10 to 48 % ( @entity1 ) between 1996 and 2007, and then remained relatively stable through to 2012. A higher proportion of @entity1 with prior @entity170 management were managed within 6 months (56 % @entity1 , 67 % @entity1 ) of chronic GC use, compared to @entity1 without prior management (12 % @entity1 , 23 % @entity1 ). @entity1 with @entity627 were managed most commonly (41 %), and @entity1 with respiratory conditions were managed least commonly (21 %). CONCLUSIONS: GC-induced @entity170 management improved significantly over time for both sexes yet remains low. Significant care gaps by sex and between clinical areas represent a missed opportunity for @entity174 prevention among @entity1 requiring chronic GC therapy.

Glucocorticoid-induced XXXX management among seniors, by year, sex, and indication, 1996-2012.

@entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'men'] @entity627 :: ('MESH:D012216', 'Disease') :: ['rheumatic conditions', 'rheumatic disease'] @entity174 :: ('MESH:D050723', 'Disease') :: ['fracture'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity170 :: ('MESH:D010024', 'Disease') :: ['Osteoporosis', 'osteoporosis']
@entity170 :: (MESH:D010024,Disease) :: ['osteoporosis']
